ArticleCureus2025
A Report of Two Cases of Embryonal Rhabdomyosarcoma: Diagnostic Insights From Pathology.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhabdomyosarcoma (RMS) is a family of malignant soft tissue tumors derived from undifferentiated mesoderm that fails to differentiate into skeletal muscle. Embryonal RMS (ERMS) is the most common subtype of RMS in children and adolescents, particularly those under 10 years of age. It primarily arises in the head and neck region, genitourinary tract, or extremities. Histologically, it resembles developing skeletal muscle with anaplastic features. Diagnosis relies on a combination of imaging, histopathology, immunohistochemistry, and molecular studies, with specific genetic alterations noted in the literature. Effective treatment of pediatric RMS cases requires multimodal therapy, including surgery, chemotherapy, and radiotherapy, to achieve a favorable prognosis. We report two cases of ERMS diagnosed within a four-month period, where immunohistochemistry and molecular studies contributed to the diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.